M. Philippe Gual

Research director (DR2 INSERM) Team Leader, Team 8 “Chronic liver diseases associated with obesity and alcohol”, INSERM U1065, C3M, Nice

Centre Méditerranéen de Médecine Moléculaire (C3M)

Coordonnées

INSERM U1065,Centre Méditerranéen de Médecine Moléculaire (C3M) Bâtiment Universitaire ARCHIMED Equipe 8"Maladies chroniques du foie associées à obésité et l'alcool" 151 route Saint Antoine de Ginestière BP 2 3194 06204 NICE

Tél: +33 4 89 15 38 35
Fax: +33 4 89 06 42 60
Téléphone 2: +33 4 89 15 38 35
Mail: Philippe.GUAL@univ-cotedazur.fr
Site internet: https://www.c3m-nice.fr/en/Teams/team-08/

Discipline(s)

Santé-Médecine > Biochimie, biologie cellulaire et moléculaire, physiologie et nutrition

Discipline(s) enseignée(s)

Teaching and Training
Training of 17 Master students, 7 PhD students, 2 Post doc
Lectures for scientific societies (Obesity, Hepatology)
Courses on "liver complications of obesity" for the Masters of “Nutrition and vascular pathology"” (University of Aix-Marseille) and of “UE Pathophysiology of obesity and cardio-metabolic diseases” and “UE of microbiology research” (University of Nice); DU Dysmetabolic Steatohepatitis (NASH) (University of Angers)
Co-head of the UE of physiology, University of Cote d’Azur (Licence)(Since 2022)

Thèmes de recherche

The aims of the present team (created in 2008), composed of clinicians and basic scientists, are to better understand the hepatic complications associated with obesity (Non alcoholic fatty liver disease: NAFLD) and with chronic alcohol consumption (alcoholic liver disease, ALD). These chronic liver diseases range from steatosis to steatohepatitis (Non Alcoholic or Alcoholic Steatohepatitis, NASH and ASH), fibrosis, cirrhosis and finally hepatocellular carcinoma. NAFLD and ALD are the main causes of cirrhosis and increase the risk of liver-related death with limited therapeutic options available. It is urgent to better diagnosis and treat these chronic liver diseases. Our translational researches mainly focus on
1) the identification of new markers/actors of the progression of these chronic liver diseases (NAFLD/ALD). We take advantage of our cohorts of obese and alcoholic patients;
2) the study of potential players in the progression of NAFLD and ALD including the cell matrix interaction- (CD44), non-receptor tyrosine kinase- and innate lymphoid cell- dependent pathways as well as metabolic pathways regulating immune functions;
3) the impact of targeting these pathways is investigated by preclinical approaches.
Over the past few years, the team have made significant contributions to provide new insights into the understanding of these chronic liver diseases in order to propose a better diagnostic and new therapeutic targets.
https://preprod-c3m.dev-thuria.com/en/Teams/team-08/

Activités / CV